Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

May 30,Johnson & Johnson announced that William Hait, Executive Vice President of the company and Chief External Innovation and Medical Officer, will officially retire in September this year.

Since joining Johnson & Johnson in 2007, Dr. Hait has been committed to combining breakthrough science with unmet medical needs, significantly improving the lives of millions of patients worldwide. As Chief External Innovation & Medical Officer, he has led the company in drawing disruptive technologies and cutting-edge science from the external innovation ecosystem, driving advancements across departments to enhance human health, while making substantial contributions to product safety and ethical research.

Dr. William Hait

Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson, said: "From leading our innovative pharmaceuticals R&D organization to his current role, Hait has played a pivotal role in driving Johnson & Johnson’s commitment to combining transformative innovation with an unwavering focus on patient care to improve human health. He fully embodies our corporate credo. Having had the privilege to work with Hait for many years, I have been deeply inspired by his wisdom, relentless pursuit of innovation, and passion for improving global patient health. Furthermore, his exceptional contributions to cultivating and developing outstanding leaders within the company will bring long-term benefits to both our organization and patients worldwide."

After Dr. Hait joined Johnson & Johnson, he established the company's innovative drug oncology therapeutic area and served as its first Global Therapeutic Area Head from 2009 to 2011.

During his tenure as the global head of innovative pharmaceuticals R&D (2011-2018) and interim head (2022-2023), the company's innovative pharmaceuticals division launched over 20 new products, including DARZALEX® (daratumumab), ERLEADA® (apalutamide), IMBRUVICA® (ibrutinib), SPRAVATO® (esketamine), TREMFYA® (guselkumab), and ZYTIGA® (abiraterone acetate), significantly improving patients' quality of life.

Before joining Johnson & Johnson, Dr. Hait was the founding director of the Rutgers Cancer Institute of New Jersey, the first and only comprehensive cancer center in New Jersey to receive designation from the National Cancer Institute. In addition, he served as a professor of medicine and pharmacology and as the associate dean of the oncology program at the Robert Wood Johnson Medical School of the University of Medicine and Dentistry of New Jersey. Earlier in his career, he was the chair of the Department of Internal Medicine Oncology at Yale University School of Medicine. Dr. Hait graduated from the University of Pennsylvania, where he earned his medical doctorate and Ph.D. with distinction from the Perelman School of Medicine.

In fact,Johnson & Johnson Medical Technology recently announced two personnel changes in China.

This month, Johnson & Johnson officially announced,Ronnie Chen will serve as the Human Resources Leader for Johnson & Johnson Medical Technologies China & OneHR China, effective April 29, 2024.

In this position, Ronnie willProvide human resources-related support for Johnson & Johnson Medical Technology's China operations from both operational and strategic perspectives.At the same time, she will be responsible for all aspects of talent strategy, including talent acquisition, promoting a culture of diversity, equity and inclusion, as well as core competency development, thereby supporting business growth.

It is reported that Chen Yanli, former Vice President of Talent and Organizational Culture at Roche Pharmaceuticals China and Head of China Market Access and Key Account Management for Hospitals, has recently left Roche.

And at the end of March,Johnson & Johnson Medical Technology announced Tulio Oliveira as the new General Manager of its Surgical Division in China.

Before joining the China team,Tulio serves as an advanced surgical specialist at Johnson & Johnson Medical Technology.StaplerGlobal Head of (Advanced Stapling) Business.Tulio joined Johnson & Johnson in 2003 as a sales representative for Ethicon in the Brazilian market. He subsequently worked in Brazil, the United States, Chile, and Argentina, with responsibilities spanning sales, marketing, new business development, global strategic marketing, strategic planning, and general management. In 2013, Tulio participated in a two-year International Development Program (IDP) in Somerville, USA. As the global leader for the advanced stapler business, Tulio managed a business with a scale exceeding 2 billion US dollars.

Before joining Johnson & Johnson, Tulio served as an officer in the Brazilian Army. Additionally, he was the founder and first chairman of the Chilean Medical Device Industry Association. The announcement at that time stated,After Tulio joins as the General Manager of the China Surgical Division, he will report directly to Song Weiqun, Global Senior Vice President of Johnson & Johnson and Chairman of Johnson & Johnson China, and serve as a member of the China Board of Directors and the Asia-Pacific Surgical Business Leadership Team.

Johnson & Johnson was founded in 1886.It is one of the most comprehensive healthcare companies in the world with a wide range of business operations, covering three major fields: medical devices, pharmaceuticals, and consumer products.Headquartered in New Brunswick, New Jersey, U.S., Johnson & Johnson operates more than 260 companies across 60 countries and regions worldwide. For over a century, the company has been committed to advancing health care, helping people stay healthy at every age and stage of life.

Among them,Johnson & Johnson'sThe medical device business coversMinimally invasive and open surgery, electrophysiology, orthopedics, and ophthalmologyItsDiversified BusinessPipeline supports Johnson & Johnson Medical to become the foreign medical device company with the highest revenue in China in recent years.

In September 2023, Johnson & Johnson announced a brand renewal.Integrate the two major businesses of medical technology and pharmaceuticals under the name of Johnson & JohnsonAmong them, the pharmaceutical business Janssen has been renamed Johnson & Johnson Innovative Medicine, while Johnson & Johnson MedTech remains unchanged.

This brand renewal,Highlighting Johnson & Johnson's cross-business comprehensive strength in the healthcare field, continuously promoting healthcare innovation,Tackle the toughest health challenges and advance the development of global health.

It should be noted that, as one of the first multinational enterprises to enter the Chinese market since the reform and opening up, for many years,Johnson & Johnson has always been committed to providing high-quality innovative products to meet the growing healthcare needs.Bring health to Chinese patients and consumers, and build a Healthy China. Today,Johnson & Johnson's global businesses, including medical devices, pharmaceuticals, consumer health, and Vision, have all entered China and have become leaders in their respective fields.

From the financial data, in the whole year of 2023, Johnson & Johnson achieved a total revenue of 85.2 billion US dollars, increasing by 6.5% year-on-year. Among these, growth was driven by electrophysiology products in the interventional solutions sector, contact lenses in the vision sector, wound closure products in the general surgery sector, and biosurgery products in the advanced surgery sector.Johnson & Johnson Medical Technology achieved revenue of $30.4 billion in 2023, representing a year-on-year increase of 10.8%.

On April 16, Johnson & Johnson's Q1 2024 earnings report showed,Its global sales reached $21.4 billion, a year-on-year increase of 2.3%.Among them,Johnson & Johnson Medical Technologies sales reached $7.8 billion, a year-on-year increase of 4.5%.Johnson & Johnson expects,Total sales for 2024 are expected to be between USD 88.7 billion and USD 89.1 billion.Higher than the previously expected range of $88.2 billion to $89.0 billion.

The financial report shows that Johnson & Johnson Medical Technology's operating income increased by 6.3% year-on-year, mainly due to electrophysiology products in the cardiovascular field.Abiomed(Previously known as Interventional Solutions) and wound closure products in the general surgery field. By business line:

▪ Cardiovascular business revenue reached $1.806 billion, representing a year-over-year increase of 20.2%.Among them, the electrophysiology business continues to lead with revenue reaching $1.344 billion, a year-on-year increase of 23%; Abiomed's revenue was $371 million, a year-on-year increase of 14.5%.

▪ Orthopedic revenue was $2.34 billion, representing a year-over-year increase of 4.3%.Among them, all four sub-sectors achieved positive growth, with hips and knees increasing by 8.1% and 9.0% year-on-year, respectively.

▪ Surgical and ophthalmic businesses have seen a partial decline, with relatively weak performance in international markets.Surgical revenue was $2.416 billion, a year-on-year decrease of 0.7%. Ophthalmic revenue was $1.258 billion, a year-on-year decrease of 3.3%.

Johnson & Johnson Chairman and CEO Du Anqing stated: "The performance Johnson & Johnson achieved in the first quarter fully demonstrates the strong strength of our more focused business and the continuous progress in our product portfolio and R&D pipeline."

——

It should be noted that in recent years, due to the constantly changing global market environment, multinational device companies have been accelerating adjustments and transformations to enhance their competitiveness. Among these,Through spin-offs, reorganizations, mergers and acquisitions, Johnson & Johnson's pace of innovative transformation has never stopped.Early April, it was also announced thatAcquisition of Shockwave for approximately $13.1 billion to strengthen the layout in cardiovascular interventions。

In response to the healthcare reform in the Chinese market, Johnson & Johnson is also continuously transitioning to new models.As one of the fastest-growing markets for digital technology globally, Johnson & Johnson is accelerating its digital transformation through strategic layouts and the launch of digital upgrades. Additionally,China is the only market outside the United States where Johnson & Johnson has established R&D centers or departments across all its businesses.

Through these R&D centers established in China, Johnson & Johnson can not only better meet local market demands but also leverage China's technological advantages to drive global innovation. In this regard, DeviceHome will continue to follow up.

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

Industry Giant to Cut 7,500 Jobs

The First China-Made Intracardiac Ultrasound Diagnostic Catheter Launched, Highly Recognized by Industry Experts

Olympus, Sale of Key Business

Instrument Family: Top 10 Endoscope Innovations in 2024

Global Leader: China-Made Imaging Giant Launches Portable Multimodal Medical Imaging System

Achieving World's First, Lithium Battery Leader Enters Healthcare

Instrument Family: Top 10 Radiotherapy Innovation Products in 2024

87.8 Billion: The Three-Year Layout of the Imaging Giant

Neusoft Medical Photon Counting CT Technology Leads the Industry, a Leader in China-Produced Medical Imaging Equipment!

The World's Largest, Continuous Layoffs

BusinessBusiness cooperation email: qxzj@landianyiliao.com